Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC

John L. Marshall, MD
Published: Friday, Dec 16, 2016



John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).

If a a survival advantage is observed in these patients, Marshall believes that this will lead to a fairly significant shift in practice for this patient population. This is especially in part to the increasing partnership reliance on interventional radiology in multidisciplinary care for CRC that is also extending out to other cancers. This is also being explored in pancreatic cancer, gastric cancer, and other tumors where liver-dominant metastases are an issue.  

Regarding Y-90, Marshall says there is likely to be next-generation or other techniques that will work to improve liver-metastatic disease. 


John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).

If a a survival advantage is observed in these patients, Marshall believes that this will lead to a fairly significant shift in practice for this patient population. This is especially in part to the increasing partnership reliance on interventional radiology in multidisciplinary care for CRC that is also extending out to other cancers. This is also being explored in pancreatic cancer, gastric cancer, and other tumors where liver-dominant metastases are an issue.  

Regarding Y-90, Marshall says there is likely to be next-generation or other techniques that will work to improve liver-metastatic disease. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x